Video Experimental Relacionado
Updated: Sep 9, 2025
11:06
Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
Published on: January 31, 2022
4.7K
[Combinaciones de dosis fijas de fármacos hipoglucémicos: el potencial de la alogliptina y la pioglitazona en la
O I Butranova1, S K Zyryanov1,2, A R Melnikova1
1Patrice Lumumba Peoples' Friendship University of Russia.
Terapevticheskii arkhiv
|August 30, 2025
Resumen
Esta revisión examina los beneficios de la combinación de alogliptina y pioglitazona para el tratamiento de la diabetes tipo 2. Analiza los datos existentes sobre su farmacodinámica, farmacocinética, eficacia y seguridad.
Área de la Ciencia:
- Endocrinología
- Farmacología
Sus antecedentes:
- La diabetes mellitus tipo 2 (DMT2) es una enfermedad crónica frecuente asociada con numerosas complicaciones.
- La terapia combinada temprana se utiliza cada vez más en el tratamiento de la DMT2.
- Las combinaciones de dosis fijas ofrecen una opción terapéutica conveniente.
Objetivo del estudio:
- Evaluar las ventajas de la combinación de alogliptina y pioglitazona en el tratamiento de la DM2.
- Para sintetizar los datos publicados sobre la farmacodinámica, farmacocinética, eficacia y seguridad de esta combinación de fármacos.
Principales métodos:
- Revisión de la literatura de los estudios publicados.
- Análisis de los datos farmacodinámicos y farmacocinéticos.
- Evaluación de la eficacia clínica y los perfiles de seguridad.
Principales resultados:
- La combinación de alogliptina y pioglitazona demuestra beneficios potenciales en el tratamiento de la DM2.
- La revisión sintetiza los datos sobre los efectos complejos de los fármacos en el cuerpo.
- Se destacan las ventajas específicas en cuanto a eficacia y seguridad.
Conclusiones:
- La combinación de alogliptina y pioglitazona presenta una estrategia terapéutica prometedora para la DM2.
- Investigaciones adicionales pueden aclarar todo el potencial de esta combinación de dosis fijas.
- Esta combinación merece consideración en la práctica clínica para los pacientes con DMT2.
Videos de Conceptos Relacionados
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
288
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
288
01:23Dipeptidyl Peptidase 4 Inhibitors
252
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
252
01:24Glucagon-like Receptor Agonists
416
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
416
01:06Oral Hypoglycemic Agents: Glinides
256
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
256
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
255
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
255
01:16Insulin: Dosing Regimen and Adverse Effects
253
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
253